非门控RET突变介导selpercatinib和pralsetinib获得性耐药的结构基础
该研究通过分析接受selpercatinib治疗后进展的RET突变甲状腺髓样癌和CCDC6-RET融合非小细胞肺癌患者的cfDNA,鉴定出溶剂前沿和铰链区的非门控RET突变。这些突变对selpercatinib和pralsetinib均交叉耐药,晶体结构揭示两种药物采用独特结合模式,避开看门突变但易受非看门突变影响。
要点
- 溶剂前沿RET G810C/S和铰链区RET Y806C/N突变可导致对selpercatinib和pralsetinib交叉耐药。
- 两种TKI以非常规模式结合RET,锚定前裂隙并环绕门控墙进入后裂隙。
- 携带非门控RET突变的患者可能对selpercatinib和pralsetinib均耐药,需考虑其他治疗策略。
核心结论
- RET溶剂前沿和铰链区突变对selpercatinib和pralsetinib均耐药。
- 两种药物以非常规模式结合RET,避免看门突变干扰但易受非看门突变影响。
研究设计与样本
- 分析一例RET突变甲状腺髓样癌患者和一例CCDC6-RET融合非小细胞肺癌患者的cfDNA,均对selpercatinib初始应答后进展。
- 在细胞培养中鉴定selpercatinib耐药RET突变并与pralsetinib交叉分析。
- 基于同步辐射高分辨率衍射数据解析RET-selpercatinib和RET-pralsetinib复合物晶体结构。
- 从39株selpercatinib耐药细胞系中鉴定RET激酶结构域突变。
主要发现
- 在RET M918T/V804M/L甲状腺髓样癌患者cfDNA中发现溶剂前沿RET G810C/S和铰链区RET Y806C/N突变。
- 在CCDC6-RET融合非小细胞肺癌患者cfDNA中检测到RET G810C突变。
- 从39株selpercatinib耐药细胞系中鉴定出三个非门控残基上的五个RET激酶结构域突变。
- 所有五个selpercatinib耐药RET突变均对pralsetinib交叉耐药。
临床怎么用
- 对selpercatinib或pralsetinib治疗后进展的患者,应进行cfDNA或组织检测以发现RET溶剂前沿或铰链区突变。
- 检出RET G810C/S或Y806C/N等非门控突变时,提示对selpercatinib和pralsetinib均耐药,需考虑其他治疗选项。
局限性
- 研究基于有限的患者样本和细胞系,非门控RET突变的临床频率和耐药程度需进一步验证。
- 晶体结构解析基于体外重组蛋白,不能完全反映细胞内复杂环境。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung cancer (NSCLC). It is critical to analyze RET mutants resistant to these drugs and unravel the molecular basis to improve patient outcomes. PATIENTS AND METHODS: Cell-free DNAs (cfDNAs) were analyzed in a RET-mutant medullary thyroid cancer (MTC) patient and a CCDC6-RET fusion NSCLC patient who had dramatic response to selpercatinib and later developed resistance. Selpercatinib-resistant RET mutants were identified and cross-profiled with pralsetinib in cell cultures. Crystal structures of RET-selpercatinib and RET-pralsetinib complexes were determined based on high-resolution diffraction data collected with synchrotron radiation. RESULTS: RETG810C/S mutations at the solvent front and RETY806C/N mutation at the hinge region were found in cfDNAs of an MTC patient with RETM918T/V804M/L, who initially responded to selpercatinib and developed resistance. RETG810C mutant was detected in cfDNAs of a CCDC6-RET-fusion NSCLC patient who developed acquired resistance to selpercatinib. Five RET kinase domain mutations at three non-gatekeeper residues were identified from 39 selpercatinib-resistant cell lines. All five selpercatinib-resistant RET mutants were cross-resistant to pralsetinib. X-ray crystal structures of the RET-selpercatinib and RET-pralsetinib complexes reveal that, unlike other TKIs, these two RET TKIs anchor one end in the front cleft and wrap around the gate wall to access the back cleft. CONCLUSIONS: RET mutations at the solvent front and the hinge are resistant to both drugs. Selpercatinib and pralsetinib use an unconventional mode to bind RET that avoids the interference from gatekeeper mutations but is vulnerable to non-gatekeeper mutations.
引用
- Subbiah V, Shen T, Terzyan SS, et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2020. PMID: 33161056. doi:10.1016/j.annonc.2020.10.599
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。